Evidence map›Paper›PMID 42220910›Full record

ArticleFrontiers in bioengineering and biotechnology2026

Aspartic acid-facilitated remineralization: a bio-inspired alternative to fluoride for enamel repair.

Angelina Ivanova, Valeriia Buzova, Diana Potapova

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Angelina IvanovaSkyLab AG, Superlab Suisse Epalinges SA, Lausanne, Switzerland.
Valeriia BuzovaSkyLab AG, Superlab Suisse Epalinges SA, Lausanne, Switzerland.
Diana PotapovaSkyLab AG, Superlab Suisse Epalinges SA, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dental enamel is constantly challenged by acidic conditions that disrupt the balance between demineralization and remineralization. Despite proven efficacy, current remineralization strategies face limitations, which prompt exploration of novel biomimetic approaches. Aspartic acid, a calcium-binding amino acid abundant in enamel matrix proteins, was hypothesized to serve as a potential enhancer of enamel remineralization. This study investigates its potential in combination with calcium sources, comparing the efficacy of these formulations to fluoride as a conventional market benchmark. Methods: The remineralization potential of the experimental formulations was evaluated using a standardized Results: While 0.5% aspartic acid alone caused enamel demineralization (mean %SMHR = -37.32 ± 24.64), its combinations with calcium sources outperformed fluoride: 0.5% Asp + 1% tricalcium phosphate system demonstrated a mean %SMHR of 42.03 ± 19.45 - significantly higher than fluoride (14.12% ± 13.40%; p = 0.0181), a system of 0.5% Asp + 1% dicalcium phosphate dihydrate in another experiment achieved a mean %SMHR of 45.43 ± 14.64- also significantly superior to fluoride (5.15% ± 4.84%, p = 0.0058). Other formulations of Asp with calcium sources showed remineralizing potential but lacked statistical superiority to fluoride. Conclusion: These results suggest that aspartic acid-calcium formulations may offer potential advantages over fluoride-based approaches in promoting enamel remineralization. However, further investigation is needed to elucidate the underlying mechanisms and establish clinical efficacy.

Indexed as

aspartic acidcalcium sourcesenamel remineralizationfluoridein vitrosurface microhardness

Identifiers

PMID42220910
PMCPMC13216666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.